Literature DB >> 4163312

Assessment of body-iron stores in cirrhosis and haemochromatosis with the differential ferrioxamine test.

P M Smith, F Studley, R Williams.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4163312     DOI: 10.1016/s0140-6736(67)91035-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  History and development of the Liver Unit.

Authors:  I G McFarlane; A L Eddleston; P M Smith; R P Thompson
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Haemochromatosis and arthritis.

Authors:  C Stubbings
Journal:  Proc R Soc Med       Date:  1976-07

3.  Iron overload in haemochromatosis.

Authors:  I W Dymock; J P Miller; B E Godfrey; R Williams
Journal:  Proc R Soc Med       Date:  1970-12

4.  Storage iron and desferrioxamine.

Authors:  J Fielding
Journal:  Proc R Soc Med       Date:  1970-12

5.  Relationship of hepatic iron concentration to histochemical grading and to total chelatable body iron in conditions associated with iron overload.

Authors:  R J Walker; J P Miller; I W Dymock; K B Shilkin; R Williams
Journal:  Gut       Date:  1971-12       Impact factor: 23.059

6.  Iron overload.

Authors:  P M Smith
Journal:  Postgrad Med J       Date:  1969-03       Impact factor: 2.401

7.  Siderosis, haemolysis or hepatonecrosis in increasing post-desferrioxamine sideruria in acute viral hepatitis?

Authors:  L A Scuro; G Dobrilla
Journal:  Postgrad Med J       Date:  1967-11       Impact factor: 2.401

8.  Idiopathic Haemochromatosis.

Authors: 
Journal:  Br Med J       Date:  1967-02-25

9.  Differential ferrioxamine test in haemochromatosis and liver diseases.

Authors:  M Barry; G Cartei; S Sherlock
Journal:  Gut       Date:  1969-09       Impact factor: 23.059

10.  Use of diethylenetriamine penta-acetic acid (D.T.P.A.) in the clinical assessment of total body iron stores.

Authors:  L W Powell; M J Thomas
Journal:  J Clin Pathol       Date:  1967-11       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.